Under the new priority voucher program (CNPV), the FDA has approved a new oral GLP-1 drug, Foundayo, offering an alternative ...
Study of almost 28,000 people also identifies genetic variants that raise the risk of gastrointestinal side effects from ...
Two genes involved in gut hormones that influence appetite and digestion may be a factor in how people respond to GLP-1 drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results